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Aim: To study the expression profile of the NaPi2b protein and its localization in breast, ovarian and lung cancer cells in relation 
to normal tissues adjacent to tumor. Methods: Immunohistochemical analysis with monoclonal antibody MX35 was applied for 
investigation of NaPi2b protein expression in breast, lung and ovarian carcinomas. Intensity of NaPi2b protein expression was 
calculated with semiquantitative scores. Results: NaPi2b (MX35) protein expression was detected in breast, lung and ovarian cancer 
cells and adjacent normal tissue. We have shown that in contrast to ovarian tumors in breast and lung tumors NaPi2b expression 
is down regulated comparing to correspondent normal tissues.  Conclusion: This study provides the data on the pattern of NaPi2b 
expression and cellular localization in breast, lung and ovarian cancers, which might be useful for understanding the mechanism 
of transport and maintenance of inorganic phosphate in cancer and normal cells, as well as for developing novel immunotherapeutic 
approaches based on MX35 monoclonal antibody.
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Cancer biomarkers provide diagnostic and prog-
nostic information on diseases that enable interven-
tions with the appropriate therapeutic agents and 
early decisions for correction of cancer therapy. 
Furthermore, cancer biomarkers are used as targets 
for immunotherapy with corresponding monoclonal 
antibodies, such as ErbB2/Herceptin.  The develop-
ment of therapeutic monoclonal antibodies (mAbs) 
directed against membrane ovarian cancer antigen 
MX35, which is overexpressed in 90% of ovarian can-
cers, is currently in progress.  Pre-clinical and Phase 
1 clinical trials with radiolabeled mAbs MX35 provided 
useful information on pharmacokinetics and tolerated 
dose in patients with ovarian cancer [1, 2]. Recent 
studies revealed the molecular nature of MX35 antigen 
as a sodium-dependent phosphate transporter NaPi2b 
[3]. Sodium-dependent phosphate transporter Na-
Pi2b (SLC34A2, NaPiIIb, Npt2) is normally expressed 
at the brush border membrane of mammalian small 
intestine and participates in the transcellular inorganic 
phosphate (Pi) absorption, contributing to the main-
tenance of phosphate homeostasis in the body [4, 5, 
6]. The expression of NaPi2b at the protein level has 
been detected in the liver [7] and at the apical surface 
of epithelial cells of mammary, salivary glands [8, 9] 
and lung [10]. In addition to ovarian cancer [11, 12], 
the overexpression of MX35/NaPi2b at the mRNA level 
has been also reported in other human malignancies, 
including papillary thyroid [13], breast [14] and lung 
[15] cancers. However, these studies have not been 
supported by data on NaPi2b protein expression 
level and its subcellular localization, with the excep-
tion of ovarian cancer [16].  There is no doubt that 
the pattern of NaPi2b expression at the protein level 
in cancer and adjacent normal tissues may uncover 
useful information for the application of therapeutic 
MX35 mAbs.
MATERIALS AND METHODS 
Tissue samples and monoclonal antibody. 
63 archive paraffin blocks of serous ovarian cancer 
(n=10), non-small cell lung carcinomas (n=11) and 
ductal breast cancer (n=10) as well as cancer adjacent 
tissues from human breast (n=4), lung (n=9), ovary 
(n=5), uterus (n=3) and oviduct (n=2) were used for im-
munohistochemical analysis with mAbs MX35 (Table). 
MAbs MX35 was kindly provided by Dr. Gerd Ritter 
from the Ludwig Institute for Cancer Research (New-
York, USA).
Immunohistochemical analysis. Immunohis-
tochemistry was performed according to standard 
protocol. Representative sections of tumor samples 
were prepared from parafﬁn blocks and stained with 
hematoxylin — eosin as previously described [17]. 
Endogenous peroxidase was quenched with H2O2 (3%) 
in PBS. After blocking of nonspeciﬁc binding by avi-
din–biotin blocking solution (Vector Laboratories, 
Burlingame, CA, USA), tissue sections were incubated 
overnight with MX35 mAb (10μg/ml) at 4 ˚C. Then, 
sections were probed with biotinylated secondary an-
tibodies for 2h at room temperature (goat anti-mouse 
biotinylated IgG, Sigma, 1:400), followed by incuba-
tion with avidin–biotin–peroxidase complex (Vector 
Laboratories, Burlingame, CA, USA). The immune 
complexes were developed with diaminobenzidine 
solution. Hematoxylin was used for counterstaining. 
Prepared slides were examined with the use of Zeiss 
Universal microscope (Zeiss, Germany); images were 
captured using digital Axiocam software.
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Calculations. Positive for NaPi2b (MX35) stain-
ing (weak, moderate or strong) in tissues was scored 
as 1 — single positive cells (<10%); 2 — positive 
staining in less them one half of cells (10% < 50%); 
3 — positive staining in more them one half of cells 
(>50%) and 0 — as no stained cells at all (Table).
RESULTS
Immunohistochemical analysis of NaPi2b expres-
sion and cellular localization was performed with 
mAbs MX35 on the panel of cancer samples (31) and 
adjacent normal tissues (23). The intensity of NaPi2b 
protein expression was calculated by applying a semi-
quantitative scoring approach (Table) as indicated 
above. The definition of NaPi2b (MX35) overexpression 
was applied when the score of immunoreactive cells 
was significantly higher in examined cancer samples, 
when compared to adjacent normal tissues.
Table. Semi-quantitative scoring of immunohistochemical staining for Na-
Pi2b (MX35) in a panel of normal and cancer tissues
Type of tissue Score0 1 2 3
Normal breast tissue (n = 4) 0 0 1 3
Breast cancer (n = 10) 8 2 0 0
Normal lung tissue (n = 9) 0 0 1 8
Lung cancer (n = 11) 5 5 0 1
Normal uterus tissue (n = 3) 0 0 1 2
Normal oviduct tissue (n = 2) 0 0 0 2
Normal ovary tissue (n = 5) 5 0 0 0
Ovarian cancer (n = 10) 0 1 1 8
Breast. In non-tumor breast tissues NaPi2b was 
localized exclusively at the apical surface of the gland 
duct’s epithelium (Fig. 1a, marked by arrow). Intensity 
of the staining was predominantly strong and the most 
of the epithelial cells were stained (Table). Breast can-
cer tissues were negative in 8 from 10 examined cases 
(see Table). Cancer cells negative for NaPi2b staining 
marked by “c” on Fig. 1, a, and 1, b.  NaPi2b positive 
staining detected in 2 breast cancer samples (Table) 
was observed on the surface of cancer cells (Fig. 1, 
c, marked by arrow) or in the nuclei of some cells 
(Fig. 1, c, marked by arrow head). Cells with nuclear 
localization of NaPi2b sometimes had morphological 
signs of death (shrinkage or swelling of the cytoplasm 
and fragmentation of the nucleus). Positive staining 
of the dead cells was clearly visible in zones of massive 
necrosis (Fig. 1, d, dead cells marked by arrow head).
Lung. Positive staining for NaPi2b expression 
was found in most epithelial cells (scored as 2 and 3) 
of normal lung tissues adjacent to cancer cells (Fig. 
2, A, and B, marked by “a” and arrows) in all studied 
cases (see Table). NaPi2b was predominantly local-
ized on the apical surface of the type 2 alveolar cells 
in normal lung tissue (Fig. 2, b, arrow). Lung cancers 
were NaPi2b negative in 5 samples (Table and Fig. 
2, a, c, 3a, cancer cells marked as “c”) and positive 
in other 6 cases.
 In the most positive cases of lung cancer NaPi2b 
staining was observed only in single cells and was 
scored as 1 (see Table), however in one case weak 
NaPi2b staining in more than one half of cancer cells 
was observed (Fig. 3, b, and c).  Despite the fact 
that membrane localization of NaPi2b in cancer cells 
a b
c d
Fig. 1. IHC staining for NaPi2b (MX35) in human breast cancer tis-
sues. a, b, c, d — surface staining marked by arrow; c — nuclear stain-
ing marked by arrow head; d — dead cells marked by arrow head; 
gl — tissue adjacent to tumor; c — tumor tissue. Magn. a-d — x400
a b
c d
Fig. 2. IHC staining for NaPi2b (MX35) in human lung cancer tis-
sues. b and d — surface staining marked by arrow; d — nuclear 
staining marked by arrow head; a — tissue adjacent to tumor; 
c — tumor tissue Magn. a-x100, b and d — x1000, c — x200
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is a more common phenomenon for all positive lung 
cancer cases (Fig. 2, d, arrow) nuclear localization 
of NaPi2b in lung cancer cells was also sometimes 
detected (Fig. 2, d, arrow head).  In case of high 
scored lung adenocarcinoma membrane (Fig. 3, d, 
marked by arrow), nuclear (Fig. 3, b, marked by ar-
row head) and cytoplasmic (Fig 3, c, marked by arrow 
head) NaPi2b positive staining was detected. Zones 
of massive necrosis in lung cancer samples usually 
contained positive staining for NaPi2b cells (Fig. 3, d) 
resembling zones of necrosis in breast cancer (Fig. 
1, d).  On the other hand, in zones of invasive growth 
strong positive staining for NaPi2b with membrane 
(Fig. 3, b, arrow) and nuclear localization (Fig. 3, b, 
arrow head) was observed.
Ovary. No positive staining for NaPi2b (MX35) was 
found in all studied ovaries (Fig. 4, a) while surface 
epithelium of the uterus (Fig. 4, b) and oviduct (Fig. 4, 
c) was intensively stained for NaPi2b (MX35) (marked 
by arrow). The summary of immunoreactive stain-
ing is presented in Table. More precise investigation 
of ovary must be performed to examine the expres-
sion of NaPi2b (MX35) in rudiments (epoophoron, 
paroophoron, mesonephros). The most of serous 
ovarian cancer samples showed strong NaPi2b stain-
ing of apical surface (Fig. 4, d, marked by arrow) of the 
cancer cells (marked as “c”) (see Table).
DISCUSSION
MAbs MX35 was generated from mice immunized 
with a cocktail of human ovarian carcinoma cells. The 
reactivity with a panel of frozen human tissues sections 
was used as hybridoma selection criteria [18]. Clinical 
studies with Fab fragments of radiolabeled MX35 an-
tibody suggest their therapeutic potential in patients 
with ovarian cancer [1, 2]. The murine MX35 antibody 
and its fragments have been currently investigated 
in preclinical studies [9] and in a phase I clinical trial 
in patients with ovarian cancer as the carrier of the 
alpha-particle-emitting astatine-211 [20, 21]. Mo-
lecular cloning of the MX35 antigen as a phosphate 
transporter NaPi2b was carried out in our laboratory 
in collaboration with the Ludwig Institute for Cancer 
Research. This study has broaden the prospects for 
application of MX35 therapeutic antibodies not only 
for diagnosis and treatment of ovarian cancer, but 
also other cancers including thyroid, breast and lung 
cancers where altered expression of NaPi2b has been 
recently described at the mRNA level [13, 14, 15]. 
However, the expression and localization of NaPi2b 
at the protein level so far has not been investigated 
in these malignancies.
In this study, we reported the analysis of NaPi2b 
protein expression in the panel of human cancers 
and adjacent normal tissues by immunohistochemical 
analysis with mAbs MX35. In agreement with previously 
published study [8, 22], we detect the expression 
of NaPi2b protein in normal lung and breast tissues. 
In lung, NaPi2b expression was shown on the apical 
surface of type 2 alveolar cells where it might be in-
a b
c d
Fig. 3. IHC staining for NaPi2b (MX35) in human lung cancer 
tissue. b and d — surface staining marked by arrow; b — nuclear 
staining marked by arrow head, c — cytoplasmic staining marked 
by arrow head. Magn. a-d — x400
a b
c d
Fig. 4. IHC staining for NaPi2b (MX35) in human normal and 
ovarian cancer tissues: a — ovary, b — uterus, c — oviduct, 
d — ovarian cancer. NaPi2b staining is marked by arrow. Magn. 
a, b and d — x400, c — x200
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volved in the re-absorption from alveolar surfactant Pi, 
which is subsequently used for phospholipid synthesis 
[22]. In normal breast tissues, an expression of NaPi2b 
protein was detected in epithelial cells of secreting 
mammary glands of caprine, where NaPi2b is possibly 
implicated in delivering Pi into milk during lactation [8]. 
We have recently reported that NaPi2b is expressed 
in oviduct and uterus, but not in ovary [12, 16]. To date, 
the function of NaPi2b in female reproductive organs 
was not examined in details. One may expect that 
NaPi2b is possibly involved in maturation of the egg 
in fallopian tubes in analogy to the role of NaPi2b 
in the epididimus where it maintains an appropriate 
level of inorganic phosphate in epididymal fluid which 
is essential for sperm maturation and male fertility [23]. 
Here, we demonstrate for the first time differential 
expression of NaPi2b on  protein level in a panel of hu-
man tumors (ovarian, lung and breast) and adjacent 
normal tissues (see Table 1). We found that NaPi2b 
protein expression in ovarian, lung and breast cancers 
is highly heterogeneous and the number of NaPi2b 
positive cells varies significantly:  from no immunore-
active staining to about 100% positively stained cells 
(see Table). The semi-quantitative analysis of NaPi2b 
expression revealed that breast and lung cancers ex-
press NaPi2b at lower level when compared to corre-
sponding normal tissues. These findings are in agree-
ment with data published by Kopantzev et al. [15], who 
reported that the expression of NaPi2b mRNA in non-
small lung cell carcinoma is significantly lower than 
that in normal lung tissues. However, our data do not 
correlate with the study by Chen et al. [14] in which 
the increased NaPi2b mRNA expression in breast 
cancer was reported. However, this discrepancy may 
reflect the difference in NaPi2b expression at mRNA 
and protein levels. So, further studies are necessary 
to explore the observed differences.
In agreement with bioinformatic predictions and 
published studies, NaPi2b showed predominantly 
cell surface localization. However, nuclear and cyto-
plasmic NaPi2b staining was also observed in breast, 
ovarian and lung cancers. Since the function of NaPi2b 
in cancer cells has not been studied so far, we can only 
suggest that NaPi2b might be involved in transport 
of inorganic phosphate via cellular membrane and 
maintaining its homeostasis. On the other hand the 
role of cytoplasmic and nuclear fractions of NaPi2b 
in cellular processes remains unclear and should 
be further investigated. Notably, nuclear and cyto-
plasmic NaPi2b staining was mainly observed in zones 
of invasive growth and massive necrosis. We can only 
speculate that cell death accompanied by the release 
of inorganic phosphate may stimulate neighboring 
cells to increase NaPi2b expression for re-absorption 
of redundant Pi from extracellular fluid.  The increased 
expression of NaPi2b in zones of invasive growth might 
reflect the requirement of proliferating cancer cells 
in Pi, as a critical component of cellular metabolic 
processes.
In summary, this study provides the data on the 
pattern of NaPi2b expression and its cellular local-
ization in breast, lung and ovarian cancers, which 
might be useful for understanding the transport and 
maintenance of inorganic phosphate in cancer and 
normal cells, as well as for development of novel 
immunotherapeutic based on MX35 mAbs. Taking 
into account that along with evident down regulation 
NaPi2b expression in breast and lung tumors, in some 
tumor samples significant number of cancer cells 
were NaPi2b positive. More precise studies of NaPi2b 
expression and localization in different tumor breast 
and lung tumor have to be accomplished.
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